Research Progress of Jianpi Qushi Powder Combined with Standard Anti Hp Quadruple Therapy in the Treatment of Hp Infectious Gastritis with Spleen Deficiency and Dampness Stagnation
StomachHelicobacter pylori infection is one of the common gastric diseases. Helicobacter pylori infectious gastritis of spleen
deficiency and dampness stagnation is a relatively intractable chronic disease.
In recent years,traditional Chinese medicine methods have emerged one after another in
the treatment of gastric Helicobacter
pylori infection. By collecting references,the
author reviewed the clinical characteristics of gastric Helicobacter pylori infection
and the new progress of traditional Chinese medicine treatment.
References
[1]
Kimura, K., Taniguchi, Y., Satoh, K., et al. (1997) Composition for the Treatment of Helicobacter pylori Infection. Kaken Pharmaceutical Co Ltd., US5618564A.
[2]
Technische Universität München and Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V. (2017) Helicobacter pylori Vaccines. World Patent Organization, WO2017102779A1.
[3]
Abadi, A. (2015) Helicobacter pylori and Gastric Cancer: Clinical Aspects. Chinese Journal of Medicine (English Version), 128, 3101-3105. https://doi.org/10.4103/0366-6999.169107
[4]
Yang, J.C., Shun, C.T., Chien, C.T. and Wang T.H. (2010) Composition for the Prevention and the Treatment of Helicobacter pylori Infection. National Taiwan University, US2010298244A1.
[5]
Shiota, S. and Yamaoka, Y. (2014) Strategy for the Treatment of Helicobacter pylori Infection. Current Pharmaceutical Design, 20, 4489-4500.
[6]
Garault, P., Bourdet-Sicard, R. and Megraud, F. (2014) Streptococcus thermophilus Strains for Treating Helicobacter pylori Infection. World Patent Organization, WO2014064488A1.
[7]
SHIONOGI & Co Ltd. (2000) Vaccine Composition for Infection of Helicobacter pylori. Shionogi & Co Ltd., JP2000083671.
[8]
Harris, A. (2001) Treatment of Helicobacter pylori. World Journal of Gastroenterology, 7, 303-307.
Jonsson, A.B. and Wehelie, R. (2011) Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection. World Patent Organization, WO2011139226A1.
[11]
Jonsson, A.B. and Wehelie, R. (2013) Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection. European Patent Office, EP2566498A1.
[12]
Go, M.F. and Fennerty, M.B. (1998) Treatment of Helicobacter pylori Infection. Current Opinion in Gastroenterology, 14, 64-69.
[13]
Coton, T., Debonne, J.M., Guisset, M., et al. (1997) L’infection a Helicobacter pylori dans les pays en developpement. Medecine Tropicale, 57, 77-82.
[14]
Lin, C.H. and Liu, T.W. (2014) Compositions and Assays for Treatment and Diagnosis of Helicobacter pylori Infection and Conditions. US8785402B2.
[15]
Chey, W.D., Leontiadis, G.I., Howden, C.W., et al. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology, 112, 212-239.
[16]
O’Connor, A., O’Morain, C.A. and Ford, A.C. (2017) Population Screening and Treatment of Helicobacter pylori Infection. Nature Reviews Gastroenterology & Hepatology, 14, 230-240.
[17]
RedHill Biopharma Ltd. (2017) Pharmaceutical Compositions for the Treatment of Helicobacter pylori. Red Hill Biopharma Ltd., US2017189341A1.
[18]
Tongtawee, T., Wattanawongdon, W. and Simawaranon, T. (2019) Effects of Periodontal Therapy on Eradication and Recurrence of Helicobacter pylori Infection after Successful Treatment. Journal of International Medical Research, 47, 875-883.
[19]
Ranjbar, R., Behzadi, P. and Farshad, S. (2017) Advances in Diagnosis and Treatment of Helicobacter pylori Infection. Acta Microbiologica et Immunologica Hungarica: A Quarterly of the Hungarian Academy of Sciences, 64, 273-292.
[20]
Dong, H., Jin, S.L. and Miao, D.L. (2017) Interpretation of ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (Version 2017). International Journal of Translational Medicine, 5, 160-166.
[21]
Okuda, M., Kikuchi, S., Mabe, K., et al. (2017) Nationwide Survey of Helicobacter pylori Treatment for Children and Adolescents in Japan. Pediatrics International, 59, 57-61.
[22]
Zhang, Y., Sun, H., Zhao, H.L., et al. (2017) Early Apoptosis of Monocytes Induced by Helicobacter pylori Infection through Multiple Pathways. Developmental & Comparative Immunology, 73, 46-51.
[23]
Ribichini, D., Castelli, V., Pasquali, R., et al. (2017) Tablet and Oral Liquid L-Thyroxine Formulation in the Treatment of Naïve Hypothyroid Patients with Helicobacter pylori Infection. Endocrine, 57, 394-401.
[24]
Ma, H., Gao, H., Huang, Y.B., et al. (2017) Efficacy Observation of Compound Lactobacillus acidophilus Combined with Conventional Quadruple Therapy in the Treatment of Peptic Ulcer Infected with Helicobacter pylori. Chinese Journal of Hospital Infectious Diseases, 27, 2932-2934, 2946.
[25]
Cui, C.C., Li, C.F. and Zhang, B. (2017) Research Status and Progress of Treatment Regimens for Helicobacter pylori Infection. Journal of Jilin University (Medical Edition), 43, 1287-1290.
